Stockscreener 앱 받기
0.6729
3.35%
-0.0233
시장 영업 전:
.67
-0.0029
-0.43%
전일 마감가:
$0.6962
열려 있는:
$0.68
하루 거래량:
709.26K
Relative Volume:
1.09
시가총액:
$88.15M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-3.0586
EPS:
-0.22
순현금흐름:
$-19.57M
1주 성능:
-10.10%
1개월 성능:
-12.12%
6개월 성능:
-55.73%
1년 성능:
-62.62%
1일 변동 폭
$0.67
$0.7072
1주일 범위
$0.67
$0.77
52주 변동 폭
$0.66
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
10202 5TH AVENUE NE, SEATTLE, WA
ATOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.6729 | 88.15M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada
Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World
Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - TipRanks
Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance
Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo Finance
Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus
Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com
Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World
Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq
Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia
Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView
Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times
Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan
Atossa Genetics stock hits 52-week low at $0.72 - Investing.com
Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa
Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat
Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC - Defense World
Market Watch Highlights: Atossa Therapeutics Inc (ATOS) Ends on an Downturn Note at 0.77 - The Dwinnex
Investing in Atossa Therapeutics Inc (ATOS) Is Getting More Attractive - Knox Daily
Atossa Therapeutics faces patent setback, continues development - MSN
FY2029 Earnings Forecast for ATOS Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat
Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Major CDC Grant Fuels Revolutionary Breast Cancer Care Program in NYC - StockTitan
Do investors need to be concerned about Atossa Therapeutics Inc (ATOS)? - US Post News
Financial Metrics Unveiled: Atossa Therapeutics Inc (ATOS)’s Key Ratios in the Spotlight - The Dwinnex
Equities Analysts Set Expectations for ATOS FY2029 Earnings - Defense World
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):